---
title: "投资者警示：Pomerantz 律师事务所代表 Capricor Therapeutics, Inc.（CAPR）的投资者进行索赔调查"
description: "Pomerantz 律师事务所正在代表 Capricor Therapeutics, Inc.（纳斯达克代码：CAPR）的投资者调查有关该公司及其高管潜在证券欺诈的索赔。在 2025 年 5 月 FDA 会议公告后，Capricor 的股票下跌了 29.13%。2025 年 6 月关于顾问委员会会议取消的后续报告导致股票价格进一步下跌 30.82%。鼓励投资者联系 Pomerantz 以获取更多信"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/252339374.md"
published_at: "2025-08-09T14:50:43.000Z"
---

# 投资者警示：Pomerantz 律师事务所代表 Capricor Therapeutics, Inc.（CAPR）的投资者进行索赔调查

> Pomerantz 律师事务所正在代表 Capricor Therapeutics, Inc.（纳斯达克代码：CAPR）的投资者调查有关该公司及其高管潜在证券欺诈的索赔。在 2025 年 5 月 FDA 会议公告后，Capricor 的股票下跌了 29.13%。2025 年 6 月关于顾问委员会会议取消的后续报告导致股票价格进一步下跌 30.82%。鼓励投资者联系 Pomerantz 以获取更多信息

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Capricor and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

**\[Click here for information about joining the class action\]**

On May 5, 2025, Capricor issued a press release announcing that after “the completion of a mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for the Company’s Biologics License Application (BLA) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy”, the FDA had “confirmed its intent to hold an advisory committee meeting” in connection with the BLA.

On this news, Capricor’s stock price fell $3.00 per share, or 29.13%, to close at $7.30 per share on May 6, 2025.

Then, on June 20, 2025 the publication STAT reported that the new head of the relevant FDA unit had canceled the advisory committee meeting for deramiocel due to uncertainty about the drug’s efficacy and safety.

On this news, Capricor’s stock price fell $3.68 per share, or 30.82%, to close at $8.26 per share on June 20, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

**CONTACT:**  
Danielle Peyton  
Pomerantz LLP  
dpeyton@pomlaw.com  
646-581-9980 ext. 7980

### Related Stocks

- [CAPR.US - Capricor治疗](https://longbridge.com/zh-CN/quote/CAPR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Capricor 治疗公司（纳斯达克股票代码：CAPR）的空头头寸减少了 69.4% | Capricor Therapeutics, Inc.（纳斯达克代码：CAPR）在 12 月份的空头头寸减少了 69.4%，卖空股份总计为 5,029,282 股。该股票开盘价为 29.29 美元，52 周最高价为 40.37 美元。分析师 | [Link](https://longbridge.com/zh-CN/news/270785955.md) |
| Capricor Therapeutics 发布投资者演示，重点介绍杜氏肌营养不良症项目和外泌体平台 | Capricor Therapeutics Inc. 发布了一份投资者演示文稿，详细介绍了其杜氏肌营养不良症治疗项目 deramiocel 的最新进展。主要亮点包括完成了预许可检查、HOPE-3 第三阶段试验的积极结果，以及计划向 FDA  | [Link](https://longbridge.com/zh-CN/news/274992906.md) |
| BUZZ-Capricor 股价上涨，因 FDA 要求提供更多数据但无需进行新的试验以用于杜氏肌营养不良症疗法 | Capricor Therapeutics 的股票在盘前交易中上涨 6.4%，至 25.90 美元，此前 FDA 要求提供其杜氏肌营养不良症治疗药物 deramiocel 的额外文件，但并未要求进行新的试验。该公司计划在 2 月份提交完整的 | [Link](https://longbridge.com/zh-CN/news/273099287.md) |
| FDA 要求提供更多 HOPE-3 数据以审查 Capricor 治疗的 Deramiocel 的批准 | Capricor Therapeutics Inc. 正在应对其生物制品许可申请（Biologics License Application）中关于 Deramiocel 的监管挑战，Deramiocel 是一种用于杜氏肌营养不良症的细胞疗 | [Link](https://longbridge.com/zh-CN/news/273097591.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。